CV-02
Target
Indication
Hit
Lead
Tox
Non-Clinical
Ph 1
Detail
S1P1
Multiple Sclerosis
Ulcerative Colitis
Alopecia
In Progress
US FDA
Target
Indication
Ph 1
S1P1
Multiple Sclerosis
Ulcerative Colitis
Alopecia
In Progress
(US FDA)
- We are developing a best-in-class candidate that targets S1P1 receptor
- Its unique mechanism of action significantly overcomes the cardiac side effects that existing approved drugs have failed to address
- Potential to expand its indications to other autoimmune diseases
